Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Phio Pharmaceuticals Corp (PHIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PHIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.44% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.51M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.87 | 52 Weeks Range 0.97 - 9.79 | Updated Date 08/15/2025 |
52 Weeks Range 0.97 - 9.79 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.43% | Return on Equity (TTM) -76.12% |
Valuation
Trailing PE - | Forward PE 0.31 | Enterprise Value 2052957 | Price to Sales(TTM) 48.01 |
Enterprise Value 2052957 | Price to Sales(TTM) 48.01 | ||
Enterprise Value to Revenue 172.2 | Enterprise Value to EBITDA 0.61 | Shares Outstanding 4798150 | Shares Floating 4754683 |
Shares Outstanding 4798150 | Shares Floating 4754683 | ||
Percent Insiders 1.14 | Percent Institutions 12.2 |
Upturn AI SWOT
Phio Pharmaceuticals Corp
Company Overview
History and Background
Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company focused on developing self-delivering RNAi therapeutics. It was formerly known as RXi Pharmaceuticals and changed its name in 2017. They are focused on oncology and immune-oncology applications.
Core Business Areas
- RNAi Therapeutics Development: Focuses on developing and commercializing RNAi-based therapeutics targeting gene expression for various diseases, particularly in cancer immunotherapy.
Leadership and Structure
Dr. Robert Bitterman serves as Chairman and CEO. The company has a board of directors and a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- INTASYLu00ae platform: A self-delivering RNAi platform used to develop therapeutic candidates. The market share of the INTASYL platform is hard to determine as it is developmental platform and isn't currently generating revenue. INTASYLu00aeis a market differentiator over traditional approaches. Competitors include Alnylam, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals (acquired by Novo Nordisk).
- PH-762: A self-delivering RNAi compound targeting tumor microenvironment. Currently in preclinical development. Competitors include companies developing similar RNAi therapies, as well as established oncology drug developers such as Roche, Novartis, and Merck.
Market Dynamics
Industry Overview
The RNAi therapeutics market is rapidly growing, driven by advancements in delivery technologies and increasing clinical validation. There is significant potential for RNAi therapies in various diseases.
Positioning
Phio Pharmaceuticals Corp is a small player in the RNAi therapeutics market, focusing on self-delivering RNAi technology. Their competitive advantage lies in their INTASYL platform and its potential for improved delivery.
Total Addressable Market (TAM)
The global RNAi therapeutics market is projected to reach billions of dollars. Phio Pharmaceuticals Corp is aiming to capture a portion of this TAM with its self-delivering RNAi platform and pipeline of therapeutic candidates. Exact figures for TAM are difficult to determine.
Upturn SWOT Analysis
Strengths
- Self-delivering RNAi platform (INTASYL)
- Focus on oncology and immune-oncology
- Experienced management team
- Early-stage pipeline with potential for high impact
Weaknesses
- Limited financial resources
- High dependence on successful clinical trials
- Small market capitalization
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new therapeutic targets
- Successful clinical trials demonstrating efficacy
- Advancements in RNAi delivery technology
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Financial instability
Competitors and Market Share
Key Competitors
- ALNY
- ARWR
- NVO
Competitive Landscape
Phio Pharmaceuticals Corp. competes with larger, more established pharmaceutical companies in the RNAi therapeutics market. Its INTASYL platform provides a potential competitive advantage, but the company faces challenges related to limited financial resources and clinical trial execution.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited by the company's development stage. However, the company is aiming to grow as its clinical programs advance and partnerships are secured.
Future Projections: Future growth is highly dependent on the success of the clinical pipeline and ability to secure partnerships. Analyst estimates should be reviewed for current projections. Analyst data is unavailable by default.
Recent Initiatives: Recent initiatives include advancing the clinical pipeline, exploring new therapeutic targets, and seeking partnerships with larger pharmaceutical companies.
Summary
Phio Pharmaceuticals Corp. is a development-stage company with an innovative RNAi platform but faces significant challenges related to funding and clinical trial success. While its INTASYL platform offers a competitive advantage, the company must overcome significant hurdles to achieve commercial success. Securing partnerships and demonstrating clinical efficacy will be crucial for its future growth. The success of the company largely depends on the outcomes of its clinical trials and any partnerships it forms.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Market Research Reports
- Yahoo Finance
Disclaimers:
The information provided is for general informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is an approximation and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phio Pharmaceuticals Corp
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2012-05-10 | President, CEO & Chairman Mr. Robert J. Bitterman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://phiopharma.com |
Full time employees 5 | Website https://phiopharma.com | ||
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.